Selegiline is an irreversible but not highly selective MAO-B inhibitor administered to gain the l-DOPA level in Parkinson therapy as well as to reach a protective effect in patients with the pre-Parkinson syndrome [3] due to reducing the concentrations of potentially hazardous by-products, such as dopaldehyde and H2O2 produced by MAO-B-catalyzed dopamine oxidation [4]. Here, MAOB is linked to Parkinson disease.